Full Press Release Details
Anchiano Therapeutics Delists Ordinary
Shares from the Tel Aviv Stock Exchange
Mass., June 18, 2019 - Anchiano Therapeutics Ltd. (Nasdaq: ANCN) ("Anchiano"), a pivotal-stage biopharmaceutical
company focused on the discovery and development of novel therapies to treat cancer, today announced that it completed the process
to voluntarily delist the company's ordinary shares from trading on the Tel Aviv Stock Exchange (TASE). Anchiano's
American Depositary Shares, each representing five of its ordinary shares, continue to be traded on the Nasdaq under the ticker
is a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with
offices in Cambridge, MA, and Jerusalem, Israel. Anchiano's most advanced product candidate, inodiftagene, is in development
as a treatment for non-muscle-invasive bladder cancer. For more information on Anchiano, please visit www.anchiano.com.
contains "forward-looking statements" that are subject to risks and uncertainties. Words such as "believes,"
"intends," "expects," "projects," "anticipates" and "future" or similar
expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties
in predicting future results and conditions, many of which are beyond the control of Anchiano, including, without limitation, the
risk factors and other matters set forth in its filings with the Securities and Exchange Commission, including its Annual Report
on Form 20-F for the year ended December 31, 2018. Anchiano undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Chief Executive Officer